🔥Telegram İfşa

Find here the new simplified index for stratifying older Hodgkin lymphoma patients as fit, unfit, or frail. haematologica.org/article/view/1…

Teclistamab based treatment in a post Transplant Relapse High risk MM, after Daratumumab failure, patient had multiple EMDs at relapse, excellent response For EMDs by Teclistamab.

As one of the principal academic beneficiaries of Dr. Brian Durie’s mentorship, guidance, and kindness I am heartbroken to hear of his passing. His contributions to myeloma and oncology are without parallel. Charismatic, brilliant, dedicated, Dr. Durie has had a huge impact on

📢 𝘋𝘰𝘯’𝘵 𝘮𝘪𝘴𝘴 𝘰𝘶𝘳 𝘯𝘦𝘹𝘵 𝘐𝘈𝘊𝘏 𝘞𝘦𝘣𝘪𝘯𝘢𝘳! 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗜𝗠𝗦 𝟮𝟬𝟮𝟱: 𝗔 𝗙𝗼𝗰𝘂𝘀 𝗼𝗻 𝗖𝗘𝗟𝗠𝗼𝗗𝘀 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘦𝘥 𝘣𝘺 𝘋𝘳. 𝘙𝘢𝘩𝘶𝘭 𝘉𝘢𝘯𝘦𝘳𝘫𝘦𝘦 🗓 𝘔𝘰𝘯𝘥𝘢𝘺, 𝘖𝘤𝘵 20 | ⏰ 6:30 𝘗𝘔 𝘊𝘌𝘛 🔗 𝗙𝗿𝗲𝗲

Our research article published in Advances in Hematology. DOI. doi.org/10.1155/ah/666…

🎓 𝘕𝘦𝘸 𝘐𝘈𝘊𝘏 𝘞𝘦𝘣𝘪𝘯𝘢𝘳 𝘰𝘯 𝘴𝘪𝘵𝘦! 𝗛𝗼𝗱𝗴𝗸𝗶𝗻 𝗹𝘆𝗺𝗽𝗵𝗼𝗺𝗮 𝗳𝗿𝗼𝗻𝘁𝗹𝗶𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆: 𝘄𝗵𝗮𝘁'𝘀 𝗻𝗲𝘄? 𝘸𝘪𝘵𝘩 𝘈𝘭𝘪 𝘉𝘢𝘻𝘢𝘳𝘣𝘢𝘤𝘩𝘪 📽️𝘕𝘰𝘸 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘰𝘯 𝘥𝘦𝘮𝘢𝘯𝘥 🔗𝘞𝘢𝘵𝘤𝘩 𝘵𝘩𝘦 𝘧𝘶𝘭𝘭 𝘸𝘦𝘣𝘪𝘯𝘢𝘳 𝘧𝘰𝘳

Kindly join tomorrow

💉 Rituximab: The B-Cell Assassin⚔️ 🧬 A chimeric monoclonal antibody (IgG1κ) targeting CD20 on pre-B and mature B cells 🚫 Not expressed on stem cells or plasma cells → allows B-cell reconstitution later ⚙️ Mechanism of Action 🎯 Binds CD20 → induces B-cell depletion

🚨 CINV control gets PERSONALIZED MyRisk Phase IV RCT in MEC, high-risk pts by risk-score 🧪 Arms: NEPA (Netupitant + Palonosetron) + DEX vs 5-HT3RA+DEX (SOC) 🎯 Primary: Complete response 0-120 h across 3 cycles 📊 Results • CR per-cycle: 81.0% vs 71.8% → OR 1.67, p=0.012

Very important one

Updated mSMART guidelines on treatment of newly diagnosed myeloma. Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. msmart.org/mm-treatment-g…

🧵 IMiDs → CELMoDs: The Evolution of Cereblon Modulation in Myeloma 💊 Immunomodulatory drugs (IMiDs) like lenalidomide/pomalidomide transformed MM therapy — but refractoriness is common after prolonged use. 📈 CELMoDs — iberdomide & mezigdomide — next-gen cereblon modulators

Breaking: And I’m glad. This is an important option we need for patients with myeloma. FDA has approved belantamab in combination with bortezomib and dex (BVd) for relapsed or refractory multiple myeloma in patients who have received at least two prior lines of therapy,

Sab ka sath, sirf ek Gujarati ka Vikas😍😍

🧬 Not all DLBCLs are created equal - POLA knows the difference. 📊 Real-world (n = 740, 2015–24) Polatuzumab used in 🔹Frontline (305) 🔹R/R (435) COO classified by Hans IHC algorithm 🔥 R/R LBCL: •ORR 59.7% vs 36.3% ➜ OR 2.6 (p<0.0001) •CR 35.7% vs 17.7% ➜ OR 2.6

"Evaluation of Leukocytosis" Manual Of Medicine

Interesting 🧐

WBMT cell therapy Symposium at Ramaiah medical college, Bengaluru